Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Hematology
•
Internal Medicine
Would you use methotrexate to treat a small T-LGL clone (<650 cells/m3), with mild pancytopenia, and associated autoimmune disease such as systemic sclerosis?
Would a better alternative be consideration of a clinical trial with ruxolitinib?
Related Questions
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
Does treating CLL reduce the risk of non-melanoma skin cancers?
In addition to supportive transfusions, do you consider other interventions for symptomatic anemia and thrombocytopenia associated with chronic neutrophilic leukemia?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
What is your approach to bone imaging in MGUS?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
In an adult patient with asymptomatic, isolated neutropenia in whom you suspect a Duffy null phenotype, at what ANC or in what situations would you do a bone marrow to look for other etiologies of neutropenia?
What are your top takeaways in Hematology from ASCO 2025?
What are your top takeaways in Hematologic Malignancies from ASH 2024?